Greenwich LifeSciences Reports Continued Reduction in Breast Cancer Recurrence Rate — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences reports a <1% annual recurrence rate in non-HLA-A*02 patients treated with GLSI-100, compared to a historical 4% rate in the Katherine study.
The data is based on 6 months of additional patient data from the open-label arm of the FLAMINGO-01 Phase III trial, involving 250 patients.
The observed recurrence rate represents an approximately 70-80% reduction compared to historical data.
The non-HLA-A*02 arm is fully enrolled, with all patients completing the primary immunization series.

The big picture

Greenwich LifeSciences' update underscores the potential of immunotherapy in reducing breast cancer recurrence rates, positioning GLSI-100 as a competitive alternative to existing treatments. The continued reduction in recurrence rates aligns with broader industry trends toward personalized and targeted cancer therapies, particularly for high-risk patients.

What we're watching

Clinical Efficacy: Whether the observed recurrence rate reduction in non-HLA-A*02 patients will be sustained or exceed historical comparisons as more data is collected.
Regulatory Pathway: The pace at which Greenwich LifeSciences can advance GLSI-100 through the Phase III trial and potential regulatory approvals.
Market Positioning: How these preliminary results position GLSI-100 against existing treatments like Kadcyla (TDM1) and Enhertu (T-DXd) in the adjuvant setting.